AstraZeneca approaches Gilead about potential merger

AstraZeneca approaches Gilead about potential merger AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease. Gilead, worth $96 billion at Friday’s close, is the creator of a drug that’s received U.S. approval for use with coronavirus patients. https://ift.tt/eA8V8J